CBS 2019
CBSMD教育中心
中 文

经皮左心耳封堵

Abstract

Recommended Article

Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial Anticoagulation in Concomitant Chronic Kidney Disease and Atrial Fibrillation: JACC Review Topic of the Week Comparison of the Efficacy and Safety Outcomes of Edoxaban in 8040 Women Versus 13 065 Men With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial Percutaneous Left Atrial Appendage Closure for Stroke Prophylaxis in Patients With Atrial Fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients With Atrial Fibrillation) Trial Extracellular Vesicles From Epicardial Fat Facilitate Atrial Fibrillation Subclinical and Device-Detected Atrial Fibrillation: Pondering the Knowledge Gap: A Scientific Statement From the American Heart Association Early Rhythm-Control Therapy in Patients with Atrial Fibrillation Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial
|<< 1 2 3 4 5 >>|

Original Research2021 Mar 20.

JOURNAL：Eur J Heart Fail. Article Link

Italian Society of Interventional Cardiology (GIse) Registry Of Transcatheter Treatment of Mitral Valve RegurgitaTiOn (GIOTTO): Impact of Valve Disease Etiology and Residual Mitral Regurgitation after MitraClip Implantation

F Bedogni; AP Rubbio; C Grasso et al. Keywords: TMVr; registry; valve disease etiology; residual mitral regurgitation

ABSTRACT

AIMS - The Italian Society of Interventional Cardiology (GIse) Registry Of Transcatheter Treatment of Mitral Valve RegurgitaTiOn (GIOTTO) was conceived in order to assess the safety and efficacy of the MitraClip therapy in Italy. Aim of the study was to assess the procedural, the mid-term outcomes and their predictors after MitraClip therapy, stratifying the results according to diagnosis of functional and degenerative mitral regurgitation (FMR vs. DMR).


METHODS AND RESULTS -  Between January 2016 and March 2020, 1659 patients were prospectively included in the GIOTTO registry (FMR 59.4% vs. DMR 40.6%). Acute Mitral Valve Academic Research Consortium (MVARC) technical success was achieved in 97.2% of patients, without differences between FMR and DMR and with sustained results at 30-day. In the available population, the rate of all-cause death was of 4.0% at 30 days, 17.5% at one-year and 34.6% at two-year. Cardiovascular death was the most frequent cause of mortality. Overall hospitalization rate was 6.3% at 30 days, 23.4% at one-year and 31.7% at two-year. The most frequent cause of hospitalization was heart failure, specifically in the early 30-day. FMR, MVARC structural and functional failures were strongly associated with one-year mortality. Residual MR 1 + (rMR) was independently related to a reduced risk of one-year mortality (HR 0.62; p = 0.005). Coherently, at two-year follow up, FMR was associated with worse outcomes than DMR, and Kaplan-Meier all-cause mortality was related to rMR.


CONCLUSIONS -  FMR etiology affects one-year mortality after MitraClip, and differences in mortality and hospitalizations can be observed between FMR and DMR within two-year. Optimal rMR 1+ was correlated to a most favorable mid-term outcome, especially in FMR.

>CBS CBS 2019

> CBS 2019 REGISTRATION

> CBS 2019 PROGRAM

> CBS 2019 CALL FOR SCIENCE

> CBS 2019 SPOTLIGHTS

 CBSMD

> CBSMD WEBSITE REGISTRATION

> EDUCATION CENTER

> RECOMMANDED PAPER

> TOP 10 RESEARCH PAPER

> PRE-READING

CBS 2019 CBS 2019 FACULTY Education Resource CBSMD Scientific Library
Copyright ⓒ CBS MD Nanjing China. All rights reserved. 京ICP备16025898号-11
联系我们| Top